

Dihydroergotamine Nasal Spray (TRUDHESA)

Criteria for Use

June 2022

VA Pharmacy Benefits Management Services, Medical Advisory Panel, and VISN Pharmacist Executives

The following recommendations are based on medical evidence, clinician input, and expert opinion. The content of the document is dynamic and will be revised as new information becomes available. The purpose of this document is to assist practitioners in clinical decision-making, to standardize and improve the quality of patient care, and to promote cost-effective drug prescribing. THE CLINICIAN SHOULD USE THIS GUIDANCE AND INTERPRET IT IN THE CLINICAL CONTEXT OF THE INDIVIDUAL PATIENT. INDIVIDUAL CASES THAT ARE EXCEPTIONS TO THE EXCLUSION AND INCLUSION CRITERIA SHOULD BE ADJUDICATED AT THE LOCAL FACILITY ACCORDING TO THE POLICY AND PROCEDURES OF ITS P&T COMMITTEE AND PHARMACY SERVICES.

The Product Information should be consulted for detailed prescribing information.

See the VA National PBM-MAP-VPE Monograph on this drug at the [PBM INTRAnet](#) site for further information.

Exclusion Criteria

If the answer to ANY item below is met, then the patient should NOT receive dihydroergotamine Nasal Spray.

- Concomitant use of strong CYP3A4 inhibitors (ritonavir, cobicistat, amiodarone, or others)
- Patients with ischemic heart disease or coronary artery vasospasm
- Deviated septum or other nasal anatomical abnormality could interfere with drug delivery.
- Patients with uncontrolled hypertension, peripheral arterial diseases, sepsis, following vascular surgery, or severe hepatic or renal impairment
- Patients with hypersensitivity to ergot alkaloids
- Concomitant use of other 5-HT₁ agonists (e.g., sumatriptan) or ergotamine containing or ergot-type medications within 24 hours
- Concomitant use of peripheral and central vasoconstrictors (midodrine, phenylephrine, pseudoephedrine, or others)
- Pregnancy

Inclusion Criteria

All of the following criteria must be met

- Diagnosis of Post traumatic headache, Cluster headache, Status migrainosus or Medication overuse headache
- Lack of therapeutic response (after at least 3 migraine episodes and a minimum of a 30-day trial), contraindication, or intolerance to generic dihydroergotamine nasal spray

Additional Inclusion Criteria

- For patients who can become pregnant: Pregnancy must be excluded prior to receiving dihydroergotamine nasal spray.
- For patients who can become pregnant: Counseling provided on potential risks vs benefits of treatment and the use of effective contraception during therapy